Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.50 |
| ▸ | PDE5A | O76074 | 4/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810313 | 0.90 | NR3C1 (0.56) | NR3C1PDE4BPDE5APGRPOLB | |
| SCHEMBL4809814 | 0.88 | PDE4B (0.58) | NR3C1PDE4BPDE5APGRLMNA | |
| SCHEMBL4817912 | 0.87 | NR3C1 (0.59) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4808277 | 0.86 | PDE4B (0.65) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4813671 | 0.86 | PDE4B (0.65) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4815888 | 0.86 | NR3C1 (0.55) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4814011 | 0.86 | NR3C1 (0.55) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4813606 | 0.86 | NR3C1 (0.55) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4816499 | 0.85 | NR3C1 (0.56) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4815773 | 0.84 | NR3C1 (0.55) | NR3C1PDE4BPDE5APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | claimed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | PDE3B, PDE3A, PDE4A | NR3C1 359/4885PDE4B 4/4885PDE5A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.